Marine Milard1, Fabienne Laugerette1, Annie Durand1, Charline Buisson1, Emmanuelle Meugnier2, Emmanuelle Loizon2, Corinne Louche-Pelissier3, Valérie Sauvinet3, Lorna Garnier4, Sébastien Viel4, Karène Bertrand5, Florent Joffre5, David Cheillan1,6, Lydie Humbert7, Dominique Rainteau7, Pascale Plaisancié1, Laure B Bindels8, Audrey M Neyrinck8, Nathalie M Delzenne8, Marie-Caroline Michalski1. 1. Univ Lyon, CarMeN Laboratory, INSERM U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, 69621, Villeurbanne, France. 2. Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69600, Oullins, France. 3. Centre de Recherche en Nutrition Humaine (CRNH) Rhône-Alpes, Centre Européen Pour la Nutrition et la Santé, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon 1, INSERM, Hospices Civils de Lyon, F-69310, Pierre Bénite, France. 4. Laboratoire d'Immunologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France. 5. ITERG-ENMS, Université de Bordeaux, Talence, France. 6. Service Biochimie et Biologie Moléculaire Grand Est, Centre de Biologie Est, Hospices Civils de Lyon, Lyon, France. 7. Sorbonne Universités, UPMC Univ. Paris 06, École normale supérieure, PSL Research University, CNRS, INSERM, APHP, Laboratoire des Biomolécules (LBM), 27 rue de Chaligny, Paris, 75005, France. 8. Louvain Drug Research Institute, Metabolism and Nutrition Research Group, Université catholique de Louvain, Brussels, Belgium.
Abstract
SCOPE: Enhanced adiposity and metabolic inflammation are major features of obesity associated with altered gut microbiota and intestinal barrier. How these metabolic outcomes can be impacted by milk polar lipids (MPL), naturally containing 25% of sphingomyelin, is investigated in mice fed a mixed high-fat (HF) diet . METHODS AND RESULTS: Male C57Bl/6 mice receive a HF-diet devoid of MPL (21% fat, mainly palm oil, in chow), or supplemented with 1.1% or 1.6% of MPL (HF-MPL1; HF-MPL2) via a total-lipid extract from butterserum concentrate for 8 weeks. HF-MPL2 mice gain less weight versus HF (p < 0.01). Diets do not impact plasma markers of inflammation but in the liver, HF-MPL2 tends to decrease hepatic gene expression of macrophage marker F4/80 versus HF-MPL1 (p = 0.06). Colonic crypt depth is the maximum in HF-MPL2 (p < 0.05). In cecal microbiota, HF-MPL1 increases Bifidobacterium animalis versus HF (p < 0.05). HF-MPL2 decreases Lactobacillus reuteri (p < 0.05), which correlates negatively with the fecal loss of milk sphingomyelin-specific fatty acids (p < 0.05). CONCLUSION: In mice fed a mixed HF diet, MPL can limit HF-induced body weight gain and modulate gut physiology and the abundance in microbiota of bacteria of metabolic interest. This supports further exploration of how residual unabsorbed lipids reaching the colon can impact HF-induced metabolic disorders.
SCOPE: Enhanced adiposity and metabolic inflammation are major features of obesity associated with altered gut microbiota and intestinal barrier. How these metabolic outcomes can be impacted by milk polar lipids (MPL), naturally containing 25% of sphingomyelin, is investigated in mice fed a mixed high-fat (HF) diet . METHODS AND RESULTS: Male C57Bl/6 mice receive a HF-diet devoid of MPL (21% fat, mainly palm oil, in chow), or supplemented with 1.1% or 1.6% of MPL (HF-MPL1; HF-MPL2) via a total-lipid extract from butterserum concentrate for 8 weeks. HF-MPL2 mice gain less weight versus HF (p < 0.01). Diets do not impact plasma markers of inflammation but in the liver, HF-MPL2 tends to decrease hepatic gene expression of macrophage marker F4/80 versus HF-MPL1 (p = 0.06). Colonic crypt depth is the maximum in HF-MPL2 (p < 0.05). In cecal microbiota, HF-MPL1 increases Bifidobacterium animalis versus HF (p < 0.05). HF-MPL2 decreases Lactobacillus reuteri (p < 0.05), which correlates negatively with the fecal loss of milk sphingomyelin-specific fatty acids (p < 0.05). CONCLUSION: In mice fed a mixed HF diet, MPL can limit HF-induced body weight gain and modulate gut physiology and the abundance in microbiota of bacteria of metabolic interest. This supports further exploration of how residual unabsorbed lipids reaching the colon can impact HF-induced metabolic disorders.
Authors: Ilse A C Arnoldussen; Martine C Morrison; Maximilian Wiesmann; Janna A van Diepen; Nicole Worms; Marijke Voskuilen; Vivienne Verweij; Bram Geenen; Natàlia Pujol Gualdo; Lonneke van der Logt; Gabriele Gross; Robert Kleemann; Amanda J Kiliaan Journal: Int J Obes (Lond) Date: 2021-10-29 Impact factor: 5.095
Authors: William R Quarles; Avi Pokala; Emily L Shaw; Joana Ortega-Anaya; Lisa Hillmann; Rafael Jimenez-Flores; Richard S Bruno Journal: Curr Dev Nutr Date: 2020-07-25